Dunad Therapeutics  is excited to welcome  Stephen Huhn, MD , as our Chief Medical Officer.   Dr. Huhn’s experience leading early translational, clinical, and regulatory strategy for complex neurodegenerative disorders marks a significant step forward as Dunad moves our development candidate into IND-enabling studies and prepares to transition into a clinical stage company.   Dr. Huhn has led early and mid-stage clinical development covering a wide range of neuroscience indic

Dunad Therapeutics is pleased to announce the formal nomination of Development Candidate, DUN’040 for the treatment of both sporadic and familial ALS . DUN’040 is a first-in-class covalent, brain-penetrant small molecule inhibitor of the lipid kinase PIKfyve that mitigates the TDP-43 proteinopathy found in 97% of all ALS patients. Modulating TDP-43 by PIKfyve inhibition represents a disease modifying therapy and a critical proximal disease target in ALS, and potentially othe

Dunad Therapeutics  is proud to announce a speaker presentation by our Associate Director,  Dr. Antony Burton, at the 2 nd  Proteomics-based Drug Discovery Summit in Boston, MA February 2-4. You can get a preview of his talk, entitled,   “Chemoproteomics discovery of a CNS-penetrant covalent inhibitor of PIKfyve” , on Biorxiv here: https://www.biorxiv.org/content/10.64898/2026.01.26.701341v1